Scholar Rock Holding Corp

Scholar Rock Holding Corp

  • Price (EUR)26.00
  • Today's Change0.40 / 1.56%
  • Shares traded0.00
  • 1 Year change+73.33%
  • Beta--
Data delayed at least 15 minutes, as of Jun 15 2021 07:11 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibodies for the treatment of diseases, such as neuromuscular disorders, cancer, fibrosis, and anemia. The Company's lead product candidate is SRK-015 that is in its pre-clinical stage of development. SRK-015 is a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle. It is used to treat spinal muscular atrophy (SMA). The Company also develops other antibody programs that include TGFβ1 and BMP6. The TGFβ1 antibody program is focused on the development of antibodies that are specific inhibitors of TGFβ1 members. It is channeled for the treatment of diseases, such as tissue and organ fibrosis, bone marrow fibrosis, and other oncologic and hematological disorders.

  • Revenue in USD (TTM)15.08m
  • Net income in USD-97.08m
  • Incorporated2017
  • Employees119.00
  • Location
    Scholar Rock Holding Corp301 BINNEY STREET, 3RD FLOORCAMBRIDGE 02142United StatesUSA
  • Phone+1 (857) 259-3860
  • Fax+1 (302) 655-5049
  • Websitehttps://scholarrock.com/
More ▼
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.